CurrentUnitedHealthcarePolicy 2026T0407HH

Intensity-Modulated Radiation Therapy

UnitedHealthcare policy for IMRT coverage for Commercial and Individual Exchange plans for individuals aged 19 years or older (IMRT for individuals <19 covered without further review). Defines proven/medically necessary indications, exceptions criteria, an unproven use, coding clarifications, and supporting evidence.

Policy Summary

PayerUnitedHealthcare

PolicyIntensity-Modulated Radiation Therapy

Policy CodePolicy 2026T0407HH

Change TypeRevisions to proven indications, wording clarifications, coding guidance

Effective DateMar 1, 2026

Next Review Date

Key ActionWhen requesting IMRT as an exception, provide treatment-plan comparisons or documentation of prior irradiation to justify IMRT over non-IMRT per RTOG/QUANTEC criteria.

SourceLink

POLICY UPDATE CHANGES

Revised list of conditions for which IMRT for Definitive Therapy for the primary site is proven and medically necessary and added several new conditions (Hepatocellular carcinoma unresectable; Hodgkin lymphoma; intrahepatic cholangiocarcinoma unresectable; rectal cancer when treatment involves inguinal lymph nodes; limited-stage small cell lung cancer; soft tissue sarcoma retroperitoneal/intra-abdominal; Stage I-II NSCLC undergoing hypofractionated RT up to 10 fractions).

Replaced phrasing for breast cancer coverage to 'breast cancer when any of the [listed] criteria are met' instead of previous wording.

Revised head and neck cancer treatment area list; replaced 'larynx (stage III or IV cancer)' with 'larynx'.

Added 'thyroid' to examples of mediastinal tumors.

Removed language that compensator-based beam modulation is proven and medically necessary when combined with an IMRT indication listed as proven.

Changed wording to indicate hippocampal-avoidance whole brain radiation therapy of up to 10 fractions is 'considered proven and medically necessary' when criteria are met.

Replaced statement that 'IMRT may be covered for a condition that is not listed as proven' with 'IMRT may be considered medically necessary for a condition that is not defined as proven and medically necessary in the policy.'

Applicable Codes: clarified billing guidance for standard single-isocenter IMRT/VMAT (CPT 77407) and use of CPT 77412 for multiple isocenters or active motion management.

Updated definition of 'Definitive Therapy' and updated Clinical Evidence and References sections.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

MultipleCovered Indications Listed

1Unproven Indication (IMRT + proton)

77407/77412CPT billing guidance codes noted

reduced toxicityIMRT advantage outcome reported

equivalentOncologic outcome vs 3D-CRT

MultipleGuidelines cited

Coverage Summary

Overview: This policy defines UnitedHealthcare Commercial and Individual Exchange coverage criteria for intensity‑modulated radiation therapy (IMRT). It applies to adults age ≥19 years (IMRT for individuals younger than 19 is covered without further review). IMRT is described as an advanced external‑beam radiation technique that modulates beam intensity to conform dose to tumor while sparing adjacent normal tissues and is often used with image guidance. The policy lists multiple proven/medically necessary indications for IMRT for definitive therapy of primary sites, includes criteria for hippocampal‑avoidance whole‑brain RT, allows case‑by‑case exceptions when non‑IMRT techniques would increase clinically meaningful normal‑tissue toxicity, and identifies one unproven use; overall coverage stance is mixed (site‑ and criteria‑specific).

Medical-Necessity Criteria

Proven and Medically Necessary - IMRT for Definitive Therapy (primary site)

Covered when ANY of the following are met:

ANY of the following

Proven and Medically Necessary - IMRT for Definitive Therapy (primary site)
- Anal canal cancer (definitive therapy).
- Breast cancer when any of the following criteria are met:
- ANY of the following
  - When the left-sided internal mammary nodes are being treated.
  - Accelerated partial-breast irradiation of up to five fractions (APBI).
    NCCN/APBI guidance: APBI up to five fractions supported for select early-stage breast cancers per guideline; use with appropriate patient selection criteria.
- Central nervous system tumors (primary or benign), including brain, brainstem, and spinal cord.
  CNS Tumors - IMRT/VMAT recommendations and evidence: IMRT/VMAT recommended to spare critical neural structures; evidence supports improved conformality and OAR sparing for complex CNS targets.
- Cervical cancer (definitive pelvic radiation).
  Cervical Cancer - IMRT preferred to reduce gastrointestinal and hematologic toxicity compared with conventional techniques; supported by guideline and trial evidence.
- Endometrial cancer (definitive or adjuvant pelvic radiation).
  Endometrial Cancer - IMRT preferred for adjuvant pelvic RT to reduce bowel and bladder dose and acute/late toxicity.
- Esophageal cancer (definitive therapy).
  Esophageal Cancer - IMRT may improve outcomes and reduce OAR dose (heart/lungs) compared with 3D techniques; observational and planning studies suggest reduced pulmonary and cardiac dose.
- Head and neck cancers, including lymphoma and solitary plasmacytomas, when treatment includes pharynx, larynx, salivary glands, oral cavity, nasal cavity, and paranasal sinuses.
  Head and Neck / Glioblastoma evidence snippet: Multiple studies demonstrate improved dose conformity and reduced xerostomia and other toxicities with IMRT; in glioblastoma IMRT/VMAT commonly used to spare normal brain.
- Hepatocellular carcinoma, unresectable.
- Intrahepatic cholangiocarcinoma, unresectable.
- Hodgkin lymphoma when mediastinal or other critical structures require sparing.
- Mediastinal tumors (e.g., lymphomas, thyroid, thymomas, tracheal cancer).
- Non-small cell lung cancer when any of the following criteria are met:
- ANY of the following
  - Stage I–II undergoing hypofractionated radiation therapy up to 10 fractions.
  - Stage III undergoing chemoradiation therapy.
- Pancreatic cancer.
- Prostate cancer.
- Rectal cancer when treatment involves inguinal lymph nodes.
- Small cell lung cancer, limited stage.
- Soft tissue sarcoma, retroperitoneal/intra‑abdominal location.
- Vulvar cancer.

Proven and Medically Necessary - Hippocampal-Avoidance Whole-Brain Radiation Therapy (HA-WBRT)

Covered when ALL of the following are met:

ALL of the following

Proven and Medically Necessary - Hippocampal-Avoidance Whole-Brain Radiation Therapy (HA-WBRT)
- Diagnosis of brain metastases (multiple metastatic lesions or prophylactic WBRT need).
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 OR Karnofsky performance status (KPS) ≥ 70.
- Prognosis of 4 months or greater.
- Absence of leptomeningeal disease.

Medically Necessary - Case-by-Case Exceptions (IMRT when not listed above)

Covered when ANY of the following are met (case-by-case exceptions):

ANY of the following

Medically Necessary - Case-by-Case Exceptions (IMRT when not listed above)
- Use of clinically appropriate radiation dose and a non-IMRT technique would increase the probability of clinically meaningful normal tissue toxicity (e.g., per RTOG or QUANTEC constraints) and this increased risk is demonstrated on a comparison of treatment plans for IMRT vs a non-IMRT technique (e.g., 3D-CRT).
  General clinical indications and rationale: IMRT provides improved dose conformity and the ability to sculpt dose away from organs at risk; decisions should reference guideline and evidence summaries showing clinical benefit in toxicity reduction or feasibility where applicable.
- The same or an immediately adjacent area has been previously irradiated and the dose distribution must be sculpted to avoid exceeding cumulative normal tissue tolerance (re-irradiation scenarios).
- Anatomic or clinical complexity (e.g., irregular target shape, multiple targets in proximity to critical structures) where IMRT/VMAT produces superior dosimetry and a clinically meaningful reduction in OAR dose compared with non-IMRT techniques.

Not Medically Necessary / Unproven

The following are Not Medically Necessary / Unproven:

ANY of the following

Not Medically Necessary / Unproven
- IMRT used in conjunction with proton beam radiation therapy.
  Insufficient evidence that combining IMRT with proton therapy provides additional clinical benefit; therefore this combination is considered unproven and not medically necessary.

Guidelines and Evidence Summary

Evidence and guideline landscape: Professional society guidelines (NCCN, ASTRO and other specialty society guidance) generally endorse IMRT or VMAT when 3D techniques cannot meet target coverage and organ‑at‑risk constraints and note consistent reductions in acute and late toxicity across tumor sites. Randomized controlled trials and large studies support toxicity benefits without loss of tumor control — examples include the PARCER trial showing reduced grade ≥2 late GI toxicity with image‑guided IMRT versus 3D‑CRT for postoperative cervical cancer, PORTEC3 secondary analysis demonstrating fewer severe GI/hematologic AEs with IMRT in endometrial cancer, RCTs (e.g., Hulshof) defining dose effects in esophageal cancer, head and neck RCTs showing reduced xerostomia and improved swallowing with IMRT/DO‑IMRT (Nutting, Tao), and hippocampal‑avoidance WBRT trials (NRG CC001/Brown et al.) showing preserved cognition with HA‑WBRT plus memantine. Despite consistent toxicity advantages, oncologic control and overall survival are generally equivalent to 3D‑CRT in many settings, and one combined modality — IMRT together with proton beam therapy in a single treatment plan — is identified as unproven.

Definitions: concise terms used in this policy are provided below (see full Definitions section for source attributions).

Coding

IMRT / Radiation Planning and Delivery CPT codes (reference)CPT

77301	Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications
77338	Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan
77387	Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed
77407	Radiation treatment delivery; Level 2, single-isocenter (e.g., 3D or IMRT), photons, including imaging guidance, when performed
77412	Radiation treatment delivery; Level 3, multiple isocenters with photon therapy or single-isocenter with active motion management, including imaging guidance, when performed
77520	Proton treatment delivery; simple, without compensation
77522	Proton treatment delivery; simple, with compensation
77523	Proton treatment delivery; intermediate
77525	Proton treatment delivery; complex

IMRT/VMAT radiation treatment delivery billing guidanceCPT

77407	radiation treatment delivery, intermediate (standard single-isocenter IMRT or VMAT)
77412	radiation treatment delivery, complex (use for treatments requiring multiple isocenters or single-isocenter delivery with active motion-management techniques); documentation must clearly justify level 3 rather than level 2

Billing guidance: Standard single‑isocenter IMRT or VMAT delivery should be billed under CPT 77407 (level 2). Use CPT 77412 (level 3) for treatments requiring multiple isocenters or single‑isocenter delivery with active motion‑management techniques; when reporting 77412, documentation must clearly justify why level 3 rather than level 2 delivery is appropriate.

Provider Actions & Billing Rules

Prior Authorization

Prior authorization recommended for advanced modalities

Prior authorization is recommended for advanced modalities (IMRT/VMAT/proton therapy) when used for indications not explicitly listed as proven in this policy or when treatment complexity (multiple isocenters, active motion management, re-irradiation, or complex OAR-sparing) is required. Include clinical indication, prior radiation history, anticipated fractionation, treatment intent (definitive, adjuvant, palliative), and comparison plans when applicable.

Billing Rule

IMRT delivery CPT code selection guidance

CPT selection guidance: Standard single-isocenter IMRT/VMAT delivery is billed with CPT 77407 (radiation treatment delivery; Level 2). CPT 77412 (radiation treatment delivery; Level 3) applies when multiple isocenters are used or when a single-isocenter approach includes active motion-management techniques or other complexity that elevates delivery to Level 3. Documentation must clearly describe the technical factors (e.g., multiple isocenters, active gating/tracking, complex field matching) that justify using 77412 instead of 77407.

Clinical Conclusions & Appropriateness Statements

Combined‑modality and compensator notes: The policy identifies that combined use of IMRT and proton beam radiation therapy in a single treatment plan is unproven and not medically necessary due to insufficient evidence. In addition, language that previously indicated compensator‑based beam modulation is proven and medically necessary when combined with listed IMRT indications has been removed; compensator‑based modulation is no longer explicitly endorsed in combination with IMRT indications in this revision.

Definitions

Key definitions:

Definitive Therapy: Radiation treatments for cancer with a curative intent.

PMRT: Postmastectomy radiation therapy targeting chest wall and ipsilateral regional nodes.

IMRT/VMAT: Advanced external‑beam techniques that modulate beam intensity to conform dose to targets while sparing normal tissues (VMAT = volumetric modulated arc therapy).

3D‑CRT: Three‑dimensional conformal radiation therapy, a conventional technique prior to IMRT.

HA‑WBRT: Hippocampal‑avoidance whole‑brain radiation therapy planned to minimize hippocampal dose to reduce cognitive decline (typical hippocampal maximum dose range reported ~ 12.61–17 Gy; exclude lesions within 5 mm of hippocampus; expected survival ≥ 4 months for consideration).

PTV: Planned target volume.

OAR: Organ at risk.

BED: Biologically effective dose (noted threshold example: BED > 80.5 Gy associated with improved outcomes in intrahepatic cholangiocarcinoma analyses).

PBRT: Proton beam radiation therapy.

Revision History

2026-03-01revisedLatest

Revised list of proven and medically necessary indications for IMRT Definitive Therapy (primary site): replaced breast phrasing to 'breast cancer when any of the listed criteria are met'; added hepatocellular carcinoma (unresectable), Hodgkin lymphoma, intrahepatic cholangiocarcinoma (unresectable), rectal cancer when treatment involves inguinal lymph nodes, limited-stage small cell lung cancer, soft tissue sarcoma (retroperitoneal/intra-abdominal), and Stage I–II NSCLC undergoing hypofractionated RT up to 10 fractions; revised head and neck treatment areas replacing 'larynx (stage III or IV cancer)' with 'larynx'; added 'thyroid' among mediastinal tumor examples.

2026-03-01revisedLatest

Replaced wording for hippocampal-avoidance whole-brain radiation therapy (HA-WBRT) to state HA-WBRT of up to 10 fractions is 'considered proven and medically necessary' when criteria are met (brain metastasis, ECOG ≤2 or KPS ≥70, prognosis ≥4 months, absence of leptomeningeal disease).

Policy Summary

PayerUnitedHealthcare

PolicyIntensity-Modulated Radiation Therapy

Policy CodePolicy 2026T0407HH

Change TypeRevisions to proven indications, wording clarifications, coding guidance

Effective DateMar 1, 2026

Next Review Date

Key ActionWhen requesting IMRT as an exception, provide treatment-plan comparisons or documentation of prior irradiation to justify IMRT over non-IMRT per RTOG/QUANTEC criteria.

SourceLink

On This Page

HA-WBRT delivered in up to 10 fractions and planned to spare bilateral hippocampi per published contouring and dose constraints.

Concurrent use of memantine as per guideline recommendations to reduce cognitive decline (HA-WBRT + memantine).

Hippocampal-Avoidance Whole-Brain Radiation Therapy (HA-WBRT) plus memantine: Clinical trials show HA-WBRT with memantine preserves cognitive function better than conventional WBRT; memantine recommended for neuroprotection during/after WBRT.

Palliation when IMRT is needed to limit dose to nearby critical organs to reduce toxicity and permit clinically meaningful symptom control.

Compensator-based beam modulation when required to achieve the intended modulation and dose distribution and when equivalent MLC-based IMRT is not feasible (IMRT technique may include compensator-based modulation).

Compensator-based beam modulation: Acceptable as a form of IMRT when documentation shows clinical equivalence and justification for use over MLC-based delivery.

Documentation Required

Plan comparison and justification for IMRT vs non-IMRT

When requesting an exception to use IMRT versus a non-IMRT technique, provide a side-by-side plan comparison (IMRT vs appropriate non-IMRT plan, e.g., 3D conformal) that documents target coverage and normal tissue doses. The comparison should reference accepted OAR tolerance guidance (RTOG or QUANTEC) and demonstrate that non-IMRT would result in clinically meaningful increased normal-tissue toxicity or unacceptable compromise of target dosing.

Documentation Required

Assess hippocampal lesion proximity and prognosis

Assess hippocampal lesion proximity and overall prognosis before selecting hippocampal-avoidance WBRT. Lesions within 5 mm of the hippocampus typically preclude hippocampal avoidance. Expectation of survival should be documented and generally be ≥ 4 months to consider hippocampal-sparing approaches.

Documentation Required

Hippocampal avoidance planning parameters

Hippocampal-avoidance planning parameters should be documented, including hippocampal dose metrics. Typical reported hippocampal maximum and D100 ranges for hippocampal avoidance WBRT are within approximately 12.61–17 Gy (depending on fractionation). Provide dose–volume histogram data for hippocampi and specify fractionation used.

Documentation Required

Plan and document OAR dose constraints

Plan and document organ-at-risk (OAR) dose constraints and provide examples when applicable. Include specific DVH reporting for relevant OARs and cumulative dose if prior radiation exists. Examples: cardiac constraints such as heart V40/V50; stomach and duodenum constraints with relevant V30-V50 thresholds; spinal cord maximum dose; lung V20/V5 when thoracic fields are involved. Demonstrate how IMRT/VMAT (or proton) achieves OAR sparing compared with non-IMRT techniques.

Heart: report V40 and V50 when relevant
Stomach/Duodenum: report V30–V50 as applicable
Spinal cord: report maximum point dose
Lung: report V20 and V5 for thoracic plans

Documentation Required

Image guidance with IMRT/VMAT

Image guidance with IMRT/VMAT requires documentation of daily IGRT and periodic 3D image assessments (e.g., cone-beam CT or surface guidance) to verify setup and anatomy. When motion or breath-hold techniques (e.g., DIBH) are used, document rationale and verification steps. Include frequency of imaging and any intrafraction monitoring used.

Documentation Required

Use of image guidance and motion management

Use of image guidance and motion management: document use of motion management strategies for mobile targets (e.g., thoracic SCLC) and daily IGRT for sites where setup/anatomic variation may affect dose delivery (rectal, thoracic, vulvar, and other pelvic or lower-abdominal sites). Describe gating, tracking, breath-hold, or other techniques and any intrafraction verification performed.

Documentation Required

Documentation to justify CPT 77412

Documentation to justify CPT 77412: When billing Level 3 delivery (77412), provide a clear description of why Level 2 (77407) is insufficient. Include technical details such as number of isocenters, complexity of field matching, use of active motion-management (gating/tracking), and any special immobilization or intrafraction monitoring that elevates delivery complexity.

Prior Authorization

Coverage requires reference to member-specific plan

Coverage requires reference to the member-specific benefit plan to determine whether IMRT, VMAT, or proton therapy is a covered benefit and any prior authorization requirements or site-specific limitations.

Billing Rule

Modality selection justification

Modality selection justification: When requesting advanced modalities (IMRT, VMAT, or proton), document that less advanced techniques cannot meet OAR constraints or target coverage requirements. Provide comparative dosimetry showing how the selected modality achieves clinically meaningful OAR sparing (per RTOG/QUANTEC or other accepted guidance), or explain why prior irradiation or complex anatomy necessitates the advanced technique.

2026-03-01revisedLatest

Replaced prior wording about coverage for non-listed conditions: now 'IMRT may be considered medically necessary for a condition that is not defined as proven and medically necessary in the policy,' including recurrences or metastases; exceptions evaluated case-by-case when plan comparisons or prior irradiation justification provided.

2026-03-01removedLatest

Removed language that compensator-based beam modulation is proven and medically necessary when combined with an IMRT indication listed as proven.

2026-03-01clarifiedLatest

Applicable codes/billing guidance clarified: standard single-isocenter IMRT/VMAT billed under CPT 77407 (level 2); use CPT 77412 for multiple isocenters or single-isocenter with active motion management, with documentation justifying Level 3 versus Level 2.

2026-03-01revisedLatest

Updated definition of 'Definitive Therapy' and refreshed Clinical Evidence and References sections.